ARCHIVES

Selumetinib Plus Docetaxel Effective in KRAS-Mutant Disease

This article is from The Cancer Letter archive.

Vol. 36 No. 1 | January 25, 2013

Download PDF Visit The Full Archive

Related Articles

EntreMed Begins Pilot Phase II Trial Of Small Molecule Angiogenesis Inhibitor.

December 15, 2000

DC Board Okay One Recompetition, Disapproves Two

November 12, 1982

Amgen Says It Can Demonstrate Safety of Existing Hg Target.

March 16, 2007

NCI Announces Designation Of Comprehensive Center

July 20, 1990

In Brief: McDonnell Foundation Selects Five For Awards; James Benson Is Named Interim FDA Head

November 24, 1989

In Brief: Hatch Restores NCI Budget Bypass Authority In His Bill Renewing National Cancer Act

April 23, 1982